Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635315 | 0.82 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL1634432 | 0.77 | FPR3 (0.31) | — | |
| SCHEMBL1633796 | 0.73 | MAPT (0.35) | — | |
| SCHEMBL4663140 | 0.70 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL1635177 | 0.67 | EPHX1 (0.33) | — | |
| SCHEMBL24588153 | 0.66 | — | — | |
| SCHEMBL1634321 | 0.61 | KMT2A (0.36) | HSD11B1 | |
| SCHEMBL3629197 | 0.60 | EPHX1 (0.36) | — | |
| SCHEMBL26934469 | 0.60 | GRM4 (0.54) | — | |
| SCHEMBL21595315 | 0.59 | KMT2A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558230-B1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | claimed |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBVIE INC. | 2004-10-14 | — | — | US | claimed |
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| US-7932245-B2 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES (US) | 2011-04-26 | — | — | US | disclosed |
| EP-1558230-B1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBVIE INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | HSD11B1 72/4885 |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | HSD11B1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.